BioCardia Completes Phase III Randomized Double-Blind Controlled Trialof Autologous Cell Therapy for Ischemic Heart Failure
BCDA Stock | USD 2.84 0.12 4.41% |
About 56% of all Biocardia's investors are looking to take a long position. The analysis of the overall investor sentiment regarding Biocardia suggests that some traders are interested. The current market sentiment, together with Biocardia's historical and current headlines, can help investors time the market. In addition, many technical investors use Biocardia stock news signals to limit their universe of possible portfolio assets.
Biocardia |
BioCardia announced today the completion of its last protocol specified follow-up visit in CardiAMP HF multi-center trial....
Read at globenewswire.com
![]() |
Biocardia Fundamental Analysis
We analyze Biocardia's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biocardia using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biocardia based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Liabilities
Current Liabilities Comparative Analysis
Biocardia is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Biocardia Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biocardia stock to make a market-neutral strategy. Peer analysis of Biocardia could also be used in its relative valuation, which is a method of valuing Biocardia by comparing valuation metrics with similar companies.
Peers
Biocardia Related Equities
ABVC | ABVC Biopharma | 9.52 | ||||
FBRX | Forte Biosciences | 7.62 | ||||
ANTX | AN2 Therapeutics | 4.67 | ||||
PTIX | Protagenic Therapeutics | 3.85 | ||||
INDP | Indaptus Therapeutics | 2.56 | ||||
ACRV | Acrivon Therapeutics, | 1.12 | ||||
MLYS | Mineralys Therapeutics, | 0.39 | ||||
AVTE | Aerovate Therapeutics | 0.41 | ||||
KTTA | Pasithea Therapeutics | 0.68 | ||||
NGENF | NervGen Pharma | 1.88 | ||||
ADAG | Adagene | 2.76 | ||||
ERAS | Erasca | 3.68 | ||||
RZLT | Rezolute | 4.16 | ||||
ANEB | Anebulo Pharmaceuticals | 7.64 |
Complementary Tools for Biocardia Stock analysis
When running Biocardia's price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data |